Rafael Holdings, Inc. SEC filings RFL
Rafael Holdings, Inc. has 409 filings in SEC EDGAR's recent list, going back to Oct 31, 2017. Its latest annual report, Form 10-K, was filed on Oct 29, 2026 for the period ended Jul 31, 2026. The latest quarterly report (Form 10-Q) was filed on Jun 11, 2026, covering the quarter ended Apr 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations, regulation fd disclosure, other events). The company's fiscal year ends on July 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Dec 11, 2025 | — |
| EFFECT | Filing | Apr 29, 2025 | — |
| CORRESP | Letter to the SEC | Apr 28, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2025 | — |
| CERT | Nyse certification | Mar 26, 2025 | — |
| 8-A12B | For registration of certain classes | Mar 17, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 14, 2025 | — |
| EFFECT | Filing | Feb 13, 2025 | — |
| CORRESP | Letter to the SEC | Feb 13, 2025 | — |
| CORRESP | Letter to the SEC | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Jan 10, 2025 | — |
| CORRESP | Letter to the SEC | Jan 8, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2025 | — |
| CORRESP | Letter to the SEC | Dec 19, 2024 | — |
| CORRESP | Letter to the SEC | Dec 19, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 11, 2024 | — |
| CORRESP | Letter to the SEC | Nov 21, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2024 | — |
| NT 10-K | Notification of late filing | Oct 30, 2024 | Jul 31, 2024 |
| 425 | Current report | Aug 22, 2024 | — |
| DEFR14A | Proxy statement | Nov 20, 2023 | — |
| EFFECT | Filing | Mar 7, 2022 | — |
| CORRESP | Letter to the SEC | Mar 3, 2022 | — |
| RW | Form rw | Feb 24, 2022 | — |
| UPLOAD | Letter from the SEC | Feb 22, 2022 | — |
| D | Filing | Aug 26, 2021 | — |
| EFFECT | Filing | Jun 17, 2021 | — |
| CORRESP | Letter to the SEC | Jun 16, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2021 | — |
| EFFECT | Filing | Jun 7, 2021 | — |
| CORRESP | Letter to the SEC | Jun 3, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 2, 2021 | — |
| EFFECT | Filing | Mar 23, 2021 | — |
| CORRESP | Letter to the SEC | Mar 19, 2021 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2021 | — |
| RW | Request for withdrawal of registration statement | Feb 8, 2021 | — |
| 25 | Notification of removal from listing | Dec 2, 2019 | — |
| CERT | Nyse certification | Nov 18, 2019 | — |
| 8-A12B | Form 8-a12b | Nov 18, 2019 | — |
| 8-A12B/A | Amendment no. 1 to form 8-a12b | Mar 27, 2018 | — |
| 10-12G/A | Amendment no. 3 to form 10 | Mar 26, 2018 | — |
| CERT | Nyse american cert-rafael holdings, inc. | Mar 5, 2018 | — |
| 8-A12B | Registration of certain classes of securities | Mar 5, 2018 | — |
| UPLOAD | Letter from the SEC | Mar 1, 2018 | — |
| CORRESP | Letter to the SEC | Feb 20, 2018 | — |
| 10-12G/A | Amendment no. 2 to form 10-12g | Feb 20, 2018 | — |
| UPLOAD | Letter from the SEC | Feb 16, 2018 | — |
| CORRESP | Letter to the SEC | Feb 1, 2018 | — |
| 10-12G/A | Amendment no. 1 to form 10-12g | Feb 1, 2018 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2018 | — |
| CORRESP | Letter to the SEC | Dec 26, 2017 | — |
| 10-12G/A | Amendment no. 1 to form10-12g | Dec 26, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 28, 2017 | — |
| 10-12G | General form for registration of securities | Oct 31, 2017 | — |
Showing 56 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RFL (NYSE)
- Fiscal year ends
- July 31
- Incorporated in
- DE
- Headquarters
- Newark, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1713863
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.